modelL01FE01

Diagram of L01FE01

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Cetuximab
ATC code:L01FE01
route:intravenous
compartments:2
dosage:400mg
volume of distribution:3.09L
clearance:0.22L/h
other parameters in model implementation

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), used in the treatment of certain types of cancer such as metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It is approved and in clinical use.

Pharmacokinetics

Population pharmacokinetic parameters in adult patients with advanced solid tumors receiving intravenous infusion.

References

  1. Shibata, K, et al., & Kawakami, J (2021). Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients. Cancer chemotherapy and pharmacology 87(4) 555–565. DOI:10.1007/s00280-020-04228-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33462734

  2. Xu, J, et al., & Ding, Y (2025). A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux. Advances in therapy 42(6) 2797–2807. DOI:10.1007/s12325-025-03193-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40232626

  3. Guo, Y, et al., & Shi, Y (2015). Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. Head & neck 37(8) 1081–1087. DOI:10.1002/hed.23707 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24710768

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)